Skip to content

OptimizeRx OPRX Free cash flow

Free cash flow at other companies

Phreesia logo
PhreesiaPHR
$19.61M+72.9%
Doximity logo
DoximityDOCS
$81.61M-17.1%
GoodRx Holdings, Inc. logo
GoodRx Holdings, Inc.GDRX
$10.7M+15.4%
PubMatic logo
PubMaticPUBM
$17.28M+21.9%
National Research Corporation logo
National Research CorporationNRC
$5.35M+46.1%
Fluent, Inc. logo
Fluent, Inc.FLNT
$5.06M+139%

Other financials

Income statement

See full
Revenue$19.8M-9.5%
Gross profit$14.9M+11.9%
Operating income$396.0K+119%
Net income-$495.0K+77.5%
EPS (diluted)-$0.03+75.0%

Balance sheet

See full
Cash & equivalents$20.2M+21.7%
Total debt$23.7M-27.7%
Total equity$129.6M+11.5%
Total assets$167.3M-0.3%

Cash flow

See full
Operating cash flow-$467.0K-112%
CapEx$21.0K-22.2%

Valuation

See full
Market cap$107.34M-54.1%
Enterprise value$110.88M-55.0%
P/E15.7×
P/S-1.2×

Profitability

See full
Gross margin70%+14.1pp
Operating margin13.2%
Net margin6.4%+3.6pp
FCF margin13.4%+4.8pp

Returns & leverage

See full
Return on equity5.6%+3.3pp
Debt / equity0.2×-0.1×
Current ratio5.4×+2.6×

Where this comes from

Calculated from OptimizeRx’s reported figures.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OptimizeRx's free cash flow?
OptimizeRx (OPRX) reported free cash flow of -$488K in Q1 2026.
How has OptimizeRx's free cash flow changed year-over-year?
OptimizeRx's free cash flow decreased by 112.7% year-over-year, from $3.84M to -$488K.
What is the long-term trend for OptimizeRx's free cash flow?
Over 2 years (2022 to 2025), OptimizeRx's free cash flow has grown at a 32.8% compound annual growth rate (CAGR), from $10.57M to $18.66M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.